Galapagos NV plans to separate into two entities: a newly to be formed company (to be named later), which would focus on building a pipeline of innovative medicines through transformational transactions, and Galapagos, which would continue to advance its cell therapies in oncology. The reorganization of its business will result in cutting approximately 300 positions across the organization in Europe, representing 40% of the company’s employees. This reorganization would result in reductions i...